Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

RemeGen Closes $100 Million Round for China Launch of Novel Biologics

publication date: Apr 6, 2020

RemeGen, a Yantai biotech, closed a $100 million funding co-led by Lilly Asia Ventures and Lake Bleu Capital. Founded in 2008, RemeGen is developing a pipeline of over ten novel biologics for autoimmune, cancer and ophthalmology diseases. The proceeds will advance commercialization of the company's two lead molecules. RC18 (telitacicept) is a fusion protein with a China NDA filed for systemic lupus erythematosus (SLE). It is also currently in Phase II or Phase III trials for six other autoimmune diseases. RC48, a HER2 ADC, is currently in pivotal clinical trials for gastric and urothelial cancers. More details....

Share this with colleagues:




This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital